Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 122, Issue 4, 2010, Pages 219-231

  Markaverich, Barry M ^a   Vijjeswarapu, Mary ^a   Shoulars, Kevin ^a,b   Rodriguez, Mary ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioflavonoid; Epidermal growth factor; Luteolin; Nuclear type II 3H estradiol binding site cell cycle; Prostate cancer

Indexed keywords

BINDING PROTEIN; CELL ANTIGEN; CELL DIVISION CYCLE 25A; CYCLIN A2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E2; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NUCLEAR PROTEIN; POLO LIKE KINASE 1; PROTEIN C FOS; PROTEIN RASGAP; SOS PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; QUINAZOLINE DERIVATIVE;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG EFFECT; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUTEOLIN; MALE; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77957277906     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.06.006     Document Type: Article

References (56)

1. Eriksson H., Upchurch S., Hardin J.W., Peck E.J., Clark J.H. Heterogeneity of estrogen receptors in the cytosol and nuclear fractions of the rat uterus. Biochem. Biophys. Res. Commun. 1978, 81(1.):1-7.
2. Clark J.H., Markaverich B., Upchurch S., Eriksson H., Hardin J.W. Nuclear binding of the estrogen receptor: heterogeneity of sites and uterotropic response. Adv. Exp. Med. Biol. 1979, 117:17-46.
3. Markaverich B.M., Schauweker T.H., Gregory R.R., Varma M., Kittrell F.S., Medina D., Varma R.S. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones. Cancer Res. 1992, 52(9):2482-2488.
4. Syne J.S., Markaverich B.M., Clark J.H., Panko W.B. Estrogen binding sites in the nucleus of normal and malignant human tissue: characteristics of the multiple nuclear binding sites. Cancer Res. 1982, 42(11):4449-4454.
5. McKenna N., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20(3):321-344.
6. Markaverich B.M., Clark J.H. Two binding sites for estradiol in rat uterine nuclei: relationship to uterotropic response. Endocrinology 1979, 105(6):1458-1462.
7. Clark J.H., Markaverich B.M. Relationships between type I and II estradiol binding sites and estrogen induced responses. J. Steroid Biochem. 1981, 15:49-54.
8. Markaverich B., Upchurch S., Clark J. Progesterone and dexamethasone antagonism of uterine growth: role for a second nuclear estrogen binding site for estradiol in estrogen action. J. Steroid Biochem. 1981, 14:125-132.
9. Watson C.S., Medina D., Clark J.H. Characterization of progesterone receptors, estrogen receptors and estrogen (type ii)-binding sites in the hormone-independent variant of the mxt-3590 mouse mammary tumor. Endocrinology 1982, 107(1):1432-1437.
10. Markaverich B.M., Gregory R.R., Alejandro M.A., Clark J.H., Johnson G.A., Middleditch B.S. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites. J. Biol. Chem. 1988, 263(15):7203-7210.
11. 3H]estradiol binding in rat uterine nuclei. J. Biol. Chem. 1983, 258(19):11663-11671.
12. 3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues. Cancer Res. 1984, 44(4):1515-1519.
13. Markaverich B.M., Gregory R.R., Alejandro M.A., Varma R.S., Johnson G.A., Middleditch B.S. Estrogen regulation of methyl p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth. J. Steroid Biochem. 1989, 33(5):867-876.
14. Markaverich B.M., Gregory R.R., Alejandro M., Kittrell F.S., Medina D., Clark J.H., Varma M., Varma R.S. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res. 1990, 50(5):1470-1478.
15. Maybruck W.M., Markaverich B.M. Partial purification and characterization of methyl-p-hydroxyphenyllactate esterase in rat uterine cytosol. Steroids 1997, 62(3):321-330.
16. 3H]estradiol binding site ligands: inhibition of ER-positive and ER-negative cell proliferation and c-Myc and cyclin D1 gene expression. Steroids 2006, 71(10):865-874.
17. Carbone A., Ranelletti F., Rinelli A., Vecchio F., Lauriola L., Piantelli M., Capelli A. Type II estrogen receptors in the papillary cystic tumor of the pancreas. Am. J. Cancer Res. 1989, 92:572-576.
18. 3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation. Int. J. Oncol. 1998, 12(5):1127-1135.
19. Piantelli M., Ricci R., Larocca L., Capelli A., Rizzo S., Scambia G., Ranelletti F. Type II estrogen binding sites in human colorectal carcinoma. J. Clin. Pathol. 1990, 43:1004-1006.
20. Scambia G., Ranelletti F.O., Benedetti Panici P., Piantelli M., Rumi C., Battaglia F., LaRocca L.M., Capelli A., Manusco S. Type II estrogen binding sites in a lymphoblastoid cell line and growth inhibitory effects of estrogen, anti-estrogen and bioflavonoids. Int. J. Cancer 1990, 46:1112-1116.
21. Larocca L.M., Teofili L., Maggiano N., Piantelli M., Ranelletti F.O., Leone G. Quercetin and the growth of leukemic progenitors. Leuk. Lymphoma 1996, 23:49-53.
22. Adlercreutz H., Mousavi Y., Hockerstedt K. Diet and breast cancer. Acta Oncol. 1992, 31:175-181.
23. Severson R.K., Nomura A.M.Y., Grove J.S., Stemmermann G.N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989, 49:1857-1860.
24. Steinmets K.A, Potter J.D. Food-group consumption and colon cancer in Adelaide case-control study. I. Vegetables and fruit. Int. J. Cancer 1993, 53:711-719.
25. Markaverich B.M., Roberts R.R., Alejandro M.A., Johnson G.A., Middleditch B.S., Clark J.H. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J. Steroid Biochem. 1988, 30(1-6):71-78.
26. 3H]estradiol binding sites and prostatic cancer cell proliferation. Int. J. Oncol. 1997, 11:1311-1319.
27. 3H]Estradiol Binding Sites as Histone H4 2001, Colorado State University, Denver.
28. 3H]estradiol binding sites: a histone H3-H4 complex. J. Steroid Biochem. Mol. Biol. 2005, 96(1):19-30.
29. 3H]estradiol binding site with recombinant histone H4. J. Steroid Biochem. Mol. Biol. 2006, 99(1):1-8.
30. Shoulars K., Rodriguez M.A., Thompson T., Markaverich B.M. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin. J. Steroid Biochem. Mol. Biol. 2010, 118(1-2):41-50.
31. Nass S.J., Dickson R.B. Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc. Clin. Cancer Res. 1998, 4(7):1813-1822.
32. Huang Y.T., Hwang J.J., Lee P.P., Ke F.C., Huang J.H., Huang C.J., Kandaswami C., Middleton E., Lee M.T. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br. J. Pharmacol. 1999, 128(5):999-1010.
33. Teraishi F, Kagawa S., Watanabe T., Tango Y., Kawashima T., Umeoka T., Nisizaki M., Tanaka N., Fujiwara T. ZD1839 (gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett. 2005, 579(19):4069-4075.
34. Sharma R.K., Chalam K.V. In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line. Acta Ophthalmol. 2009, 87(6):618-622.
35. Li C., Wong W. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:31-36.
36. Li C., Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001, 2. (RESEARCH0032).
37. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol. 2000, 60(8):1051-1059.
38. Santiskulvong C., Sinnett-Smith J., Rozengurt E. EGF receptor function is required in late G(1) for cell cycle progression induced by bombesin and bradykinin. Am. J. Physiol. Cell Physiol. 2001, 281(3):C886-C898.
39. Way T.D., Lee J.C., Kuo D.H., Fan L.L., Huang C.H., Lin H.Y., Shieh P.C., Kuo P.T., Liao C.F., Liu H., Kao J.Y. Inhibition of epidermal growth factor receptor signaling by Saussurea involucrata, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells. J. Agric. Food Chem. 2010, 58(6):3356-3365.
40. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78(1):67-74.
41. Paunesku T., Mittal S., Protic M., Oryhon J., Korolev S., Joachimiak A., Woloschak G. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int. J. Radiat. Biol. 2001, 77(10):1007-1021.
42. Johnson D.G., Walker C.L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 1999, 39:295-312.
43. Sgambato A., Camerini A., Faraglia B., Ardito R., Bianchino G., Spada D., Boninsegna A., Valentini V., Cittadini A. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J. Cell. Physiol. 2004, 201(1):97-105.
44. Gry M., Rimini R., Stromberg S., Asplund A., Ponten F., Uhlen M., Nilsson P. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 2009, 10:365.
45. Scott S.L., Earle J.D., Gumerlock P.H. Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation. Cancer Res. 2003, 63(21):7190-7196.
46. Chan Q.K., Lam H.M., Ng C.F., Lee A.Y., Chan E.S., Ng H.K., Ho S.M., Lau K.M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ. 2010.
47. Wu B, Zhang Q., Shen W., Zhu J. Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. Mol. Cell. Biochem. 2008, 313(1-2):125-132.
48. Markaverich B.M., Roberts R.R., Alejandro M.A., Johnson G.A., Middleditch B.S., Clark J.H. Bioflavonoid interactions with rat uterine type II binding sites and cell growth inhibition. J. Steroid Biochem. 1988, 30:71-78.
49. 3H]estradiol binding sites in MCF-7 human breast cancer cells: binding interactions with 2,6-bis([3,4-dihydroxyphenyl]-methylene)-cyclohexanone esters and inhibition of cell proliferation. Int. J. Oncol. 1994, 4:1291-1300.
50. Shoulars K., Brown T., Alejandro M.A., Crowley J., Markaverich B.M. Identification of nuclear type II [(3)H]estradiol binding sites as histone H4. Biochem. Biophys. Res. Commun. 2002, 296(5):1083-1090.
51. Ang K., Berkey B., Tu X., Zhang H.-Z., Katz R., Hammond E., Fu K., Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002, 62:7350-7356.
52. Tari A.M., Hung M.C., Li K., Lopez-Berestein G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene 1999, 18(6):1325-1332.
53. Suzuki T, Yonemura K., Maruyama Y., Takahashi T., Takita T., Furuhashi M., Hishida A. Impact of serum parathyroid hormone concentration and its regulatory factors on arterial stiffness in patients undergoing maintenance hemodialysis. Blood Purif. 2004, 22(3):293-297.
54. Glover C.E., Gurley K.E., Kim K.H., Storer B., Fero M.L., Kemp C.J. Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer. Carcinogenesis 2009, 30(6):1058-1063.
55. Bianco R., Caputo R., Caputo R., Damiano V., De Placido S., Ficorella C., Agrawal S., Bianco A.R., Ciardiello F., Tortora G. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin. Cancer Res. 2004, 10(14):4858-4864.
56. Fang J., Zhou Q., Shi X.L., Jiang B.H. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 2007, 28(3):713-723.